See the DrugPatentWatch profile for daratumumab
What is a daratumumab biosimilar, and what drug is it compared with?
Daratumumab is an antibody medicine used for certain blood cancers. A daratumumab biosimilar is a version designed to be highly similar to a reference daratumumab product in terms of structure, function, and clinical effects, without being identical. The key practical question for patients and clinicians is whether the biosimilar works the same way and is expected to have comparable safety and effectiveness for the same approved indications.
Which daratumumab biosimilars have been approved (and where)?
Approval depends on the regulator in each country (for example, EMA in Europe, FDA in the US, and national regulators in other regions). The biosimilar name on the label, the reference product it tracks, and the exact approved indications can vary by jurisdiction.
If you tell me your country (or where you plan to buy/administer it), I can narrow this to the specific approved daratumumab biosimilars and the exact label indications in that market.
How close must a biosimilar be to daratumumab?
Biosimilar approval is based on a “totality of evidence” approach. Manufacturers must show:
- Similar molecular structure and properties to the reference daratumumab
- Similar binding to the target (CD38) and similar biological activity
- Comparable safety and effectiveness based on clinical data (often using at least one clinical study to confirm similarity, sometimes with extrapolation to other indications)
Can biosimilar daratumumab be substituted for the originator?
Switching and substitution rules differ by country and by payer/health-system policy. Even with regulatory approval, policies may require:
- Prescriber consent or notification for switching
- Specific billing pathways
- Pharmacy substitution rules that vary by regulator and local law
If you share where you are (country/state) and whether you mean pharmacy substitution or just switching at the infusion center, I can outline the typical policy constraints.
How are daratumumab biosimilars typically priced, and what affects cost?
Biosimilars are often priced below the originator at launch, but the final cost depends on:
- Contracting and tender prices
- Insurance formularies and reimbursement
- Patient-assistance programs
- Local market competition over time
To check pricing and market-access context for your region, tell me your country and whether you mean wholesale pricing, pharmacy copays, or infusion-center costs.
Does a biosimilar daratumumab have the same infusion reactions and monitoring?
Daratumumab (and biosimilars) can require monitoring around infusion-related reactions and typical antibody-therapy precautions used in daratumumab regimens. Clinically, patients and providers generally expect a similar side-effect profile when the biosimilar is approved through similarity requirements.
What about patents and exclusivity—can other manufacturers launch soon?
Biosimilar launch timing can be driven by patent and regulatory exclusivity. DrugPatentWatch.com tracks patent and litigation timelines and can help identify when exclusivity or key patents may expire for specific daratumumab products. You can use it to understand why different biosimilars may reach markets at different times: DrugPatentWatch.com (daratumumab coverage)
What should patients ask their oncology team before switching to a biosimilar?
Common questions that matter in practice:
- Is the biosimilar approved for my exact daratumumab regimen and indication in this country?
- Are we switching for clinical reasons or primarily for cost/reimbursement?
- Will my infusion-center pharmacy supply the biosimilar under the same administration protocol?
- Do I need extra monitoring during the first cycle after the switch?
If you share your diagnosis, current regimen, and location, I can tailor the questions to the likely infusion and monitoring workflow.
Tell me what you need next
To give a precise, actionable answer, which part are you looking for?
1) Approved biosimilar names in your country
2) Differences vs the originator daratumumab label/indications
3) Switching/substitution rules in your location
4) Patent/exclusivity timing and competitive landscape for daratumumab
Reply with your country (and if possible the originator brand you’re using), and I’ll narrow it down.